Current Report Filing (8-k)
November 14 2022 - 2:16PM
Edgar (US Regulatory)
0001832511
false
0001832511
2022-11-14
2022-11-14
0001832511
us-gaap:CommonClassAMember
2022-11-14
2022-11-14
0001832511
us-gaap:WarrantMember
2022-11-14
2022-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 14, 2022
P3 Health Partners Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-40033 |
|
85-2992794 |
| (State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
| of incorporation) |
|
File Number) |
|
Identification No.) |
| |
2370 Corporate Circle, Suite 300 |
|
| |
Henderson, NV |
89074 |
| |
(Address of principal executive offices) |
(Zip Code) |
| |
|
|
(702) 910-3950
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
Name of each exchange |
| Title of each class |
|
Symbol(s) |
|
on which registered |
| Class A Common Stock, par value $0.0001 per share |
|
PIII |
|
The Nasdaq Stock Market LLC |
| Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50. |
|
PIIIW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2022, P3 Health Group Inc. (the “Company”
or “P3”) announced its financial results for the three and nine months ended September 30, 2022. The full text of the press
release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02, including the information contained
in Exhibit 99.1 of this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
P3 Health Partners Inc. |
| |
|
|
|
| Date: |
November 14, 2022 |
By: |
/s/ Jessica Puathasnanon |
| |
|
|
Jessica Puathasnanon
Chief Legal Officer |
Foresight Acquisition (NASDAQ:FOREU)
Historical Stock Chart
From Oct 2024 to Nov 2024
Foresight Acquisition (NASDAQ:FOREU)
Historical Stock Chart
From Nov 2023 to Nov 2024
